Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
Because dual incretin agonists improve metabolic dysfunction so effectively, pharmaceutical firms are heavily investing in label expansions and pipeline drugs, like emerging triple-incretin agonists
GIP receptor activation may further support insulin secretion and metabolic regulation
PCA of the pancreatic proteome showed that GLP-1GIPLani induced a clear shift relative to GLP-1GIP (Extended Data Fig
Refreshingly low pressure
US$ 23.30
US$ 20.58
US$ 21.51
US$ 26.49
US$ 22.93
US$ 20.25
US$ 27.82
